Khandelwal Laboratories Private Limited has made a slump sale of their non-oncology prescription formulation business, undertaken on a going-concern basis, to Auro Pharma Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, for ₹325 crore.
Vritti Law Partners advised Khandelwal Laboratories on this slump sale. The Firm's role included transaction structuring, drafting and negotiation of definitive documents, and closing related support.
The transaction team consisted of Arvind Ramesh (Partner), Nitin Jeswani (Principal Associate), Associates Donovan Nazareth, Vaishnavi Kanchan and Divya Mall.
Trilegal advised Auro Pharma on this acquisition. The Firm provided end-to-end legal support on the transaction, including conducting legal due diligence, drafting and negotiating the transaction documents, and assisting with closing.
The transaction team was led by Siddharth Dang (Partner), with support from Rutvi Shrimankar (Senior Associate), and Associates Sanchit Thapliyal, Rohan Singhal, Shubh Jaiswal.
Kirti Balasubramanian (Partner) and Hitarth Parikh (Associate) advised on Intellectual Property law aspects.
Parvathy Tharamel (Partner), with support from Associates Koshy Mathen, Gokul Suresh Nair advised on Employment law aspects.
The Due Diligence Team advising on the matter was led by Siddharth Dang (Partner), Ankit Kejriwal (Partner), Kirti Balasubramanian (Partner) and Parvathy Tharamel (Partner), with support from Rutvi Shrimankar (Senior Associate), Rutvij Naik (Senior Associate) and Associates Sanchit Thapliyal, Shubh Jaiswal, Hitarth Parikh, Dhanush T, Koshy Mathen, Gokul Suresh Nair.
Khandelwal Laboratories is a privately held pharmaceutical company engaged in research and development, manufacturing, distribution, marketing and licensing of pharmaceutical formulations, novel drug delivery systems (NDDS) and niche active pharmaceutical ingredients (APIs), and is a mid-segment player in the Indian market across oncology, antibiotics, and pain and spasm management therapeutic segments.
Auro Pharma is engaged in the business of formulating, manufacturing and commercialising a wide range of generic pharmaceuticals, APIs and injectables in several countries with a multi-product portfolio.
If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.